Abstracts Archive - Page 2172 of 2425 - ACR Meeting Abstracts

Abstract Number: 1190 • 2013 ACR/ARHP Annual Meeting
The Synergistic Effects Of Metabolic Syndrome Indicators and Hyperuricemia In Contributing To Cardiac Event Risk: A Cross-Sectional Examination Of The Nhanes III Data
Daniel A. Albert^1,2 and Sayyad Kyazimzade³, ¹Medicine/Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Rheumatology, The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, ³The Dartmouth Institute for Health Policy & Clinical Practice, Lebanon, NH, Lebanon, NH
Background/Purpose: The focus of this project is to assess the contribution of hyperuricemia and gout to the risk for cardiovascular events. In a preliminary analysis…
Abstract Number: 1191 • 2013 ACR/ARHP Annual Meeting
Low-Dose Anakinra Is Effective For The Prophylaxis Of Acute Episodes Of Inflammation In Severe Tophaceous Gout
Fernando Perez-Ruiz^1,2, Ana M. Herrero-Beites³, Monike de Miguel⁴ and Joana Atxotegi^5,6, ¹BioCruces Health Research Institute, Baracaldo, Spain, ²Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain, ³Physical Medicine Division, Hospital de Gorliz, Gorliz, Spain, ⁴Pharmacy Division, Hospital Universitario Cruces, Baracaldo, Spain, ⁵Rheumatology Division, Hospital de Cruces, Baracaldo, Spain, ⁶BioCruces Health Institute, Baracaldo, Spain
Background/Purpose: anakinra has been used off-label for the treatment of severe episodes of acute inflammation (EAIs) in gout. Only a retrospective series of 3 patients…
Abstract Number: 1192 • 2013 ACR/ARHP Annual Meeting
Pharmacovigilance Update On Pegloticase For Treatment Refractory Gout: United States Clinical Experience Demonstrates The Value Of Serum Uric Acid Monitoring As a Biomarker Of Risk and Efficacy
Robert T. Keenan¹, Raymond L. Malamet², Tina L. Howson³ and Kenneth M. Bahrt⁴, ¹Rheumatology, Duke University, Durham, NC, ²Global Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ, ³Savient Pharmaceuticals, Inc., Bridgewater, NJ, ⁴Medical Affairs, Savient Pharmaceuticals, Inc., Bridgewater, NJ
Background/Purpose: Pegloticase was approved in the US in late 2010 for patients with chronic gout refractory to xanthine oxidase inhibitors (XOIs). The clinical development program…
Abstract Number: 1193 • 2013 ACR/ARHP Annual Meeting
Target Tophus Size and Complete Response Rates In Patients Treated With Open-Label Pegloticase For Chronic Gout Refractory To Conventional Therapy
Robert T. Keenan¹, Nicola Dalbeth² and Herbert S. B. Baraf³, ¹Rheumatology, Duke University, Durham, NC, ²Medicine, University of Auckland, Auckland, New Zealand, ³Arthritis & Rheumatism Associates, PC, Wheaton, MD
Background/Purpose: Pegloticase, a methoxyPEG-conjugated mammalian recombinant uricase, has been approved in the US and EU for the treatment of chronic gout refractory to xanthine oxidase…
Abstract Number: 1167 • 2013 ACR/ARHP Annual Meeting
A Possible Mechanism Of NLRP3 Inflammasome Hypersensitivity In Cryopyrin-Associated Periodic Syndrome
Sayaka Ito, Chie Tagami, Yukichi Hara and Tetsuo Kubota, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: NLRP3 in monocytes and other cell types plays a role in innate immunity as one of the intracellular pathogen recognition receptors, and its mutation…
Abstract Number: 1153 • 2013 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Synovial Fibroblasts Lack Tolerization Of Inflammatory Cytokines and Matrix Degrading Enzymes After Repeated LPS Stimulation
Kerstin Klein¹, Renate E. Gay², Christoph Kolling³, Adrian Ciurea⁴, Beat A. Michel⁵, Lih-Ling Lin⁶, Steffen Gay¹ and Caroline Ospelt¹, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ³Schultess Clinic, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, University Hospital Zurich, Zurich Schlieren, Switzerland, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁶Inflammation and Remodeling Research Unit, Pfizer, Cambridge, MA
Background/Purpose: In macrophages, repeated stimulation of Toll-like receptor (TLR) 4 leads to adaptation of signaling pathways and epigenetic modifications resulting in a tolerant state of…
Abstract Number: 1154 • 2013 ACR/ARHP Annual Meeting
Poly(I:C)-Induced Cell Death Of Synovial Fibroblasts via an Unknown dsRNA Receptor
Jörg Hamann¹, Paul P. Tak² and Olga N. Karpus³, ¹Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Departments of Experimental Immunology and Internal Medicine, GlaxoSmithKline U.K. and Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³1Departments of Experimental Immunology and Internal Medicine, Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by hyperplasia of the synovial tissue due to local proliferation of stromal and recruitment of inflammatory immune cells. Accumulation…
Abstract Number: 1156 • 2013 ACR/ARHP Annual Meeting
Suppression Of Immune Responses and Joint Inflammation By Myeloid-Derived Suppressor Cells In a T Cell-Dependent Mouse Model Of Rheumatoid Arthritis
Katalin Mikecz¹, Julia Kurko¹, Timea Ocsko¹, Andras Vida¹, Beata Tryniszewska¹, Tibor A. Rauch¹, Joel A. Block², Robert S. Katz³, Anjali Nair², Carla R. Scanzello⁴ and Tibor T. Glant¹, ¹Orthopedic Surgery, Rush University Medical Center, Chicago, IL, ²Section of Rheumatology, Rush University Medical Center, Chicago, IL, ³Rush Medical College, Chicago, IL, ⁴Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of innate immune cells with immunosuppressive properties. We previously identified MDSCs in the synovial fluid (SF)…
Abstract Number: 1157 • 2013 ACR/ARHP Annual Meeting
Peptidylarginine Deiminase Inhibition Prevents Neutrophil Extracellular Trap Formation, Modulates Innate Immune Responses, and Reduces Vascular Damage In Mice
Jason S. Knight¹, Wei Luo², Alexander A. O'Dell¹, Wenpu Zhao³, Venkataraman Subramanian⁴, Chiao Guo², Robert C. Grenn³, Paul Ryan Thompson⁴, Daniel T. Eitzman² and Mariana J. Kaplan⁵, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan Cardiology, Ann Arbor, MI, ³University of Michigan Rheumatology, Ann Arbor, MI, ⁴The Scripps Research Institute, Jupiter, FL, ⁵Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Neutrophil extracellular trap (NET) formation promotes vascular damage, while stimulating interferon alpha (IFN-α) production in diseased arteries. Patients with rheumatoid arthritis and systemic…
Abstract Number: 1158 • 2013 ACR/ARHP Annual Meeting
Decreased NK-Cell Numbers and Upregulation Of Markers Of Systemic Inflammation In Autoantibody –Positive Arthralgia Patients and Early Rheumatoid Arthritis Patients But Not In Autoantibody-Negative Rheumatoid Arthritis Patients
Paulina Chalan¹, Johan Bijzet², Kornelis S.M. van der Geest¹, Bart-Jan Kroesen³, Annemieke M.H. Boots^4,5 and Elisabeth Brouwer¹, ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Dept. of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁴Dept. of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁵Groningen Research initiative on healthy Ageing and Immune Longevity (GRAIL), Groningen, Netherlands
Background/Purpose: Identification of seropositive individuals at risk for arthritis development would open opportunities for early clinical intervention. In a recent study on seropositive arthalgia patients…
Abstract Number: 1159 • 2013 ACR/ARHP Annual Meeting
Exercise Suppresses Systemic Inflammation Via Inhibition Of NF-κB Activation In Monocytes
Alisa Blazek¹, Derrick Knapik², Lai-Chu Wu³, Nicholas A. Young³, Wael N. Jarjour⁴ and Sudha Agarwal⁵, ¹Molecular, Cellular and Developmental Biology, The Ohio State University, Columbus, OH, ²College of Medicine, The Ohio State University, Columbus, OH, ³Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Division of Rheumatology and Immunology, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Inflammation is integral to joint damage and bone erosion in rheumatoid arthritis. We reported previously that physiologic levels of exercise are anti-inflammatory and suppress local…
Abstract Number: 1160 • 2013 ACR/ARHP Annual Meeting
Oxidative Stress As a Disease Marker and Therapeutic Target In Patients With Tumor Necrosis Factor Receptor Associated Periodic Fever Syndrome
Cornelia Cudrici¹, Ariel Bourla¹, Martin Pelletier², Leah Billingham¹, Amanda K. Ombrello³, Michael Murphy⁴, Daniel L. Kastner⁵ and Richard M. Siegel⁶, ¹NIAMS, Immunoregulation Section, Autoimmunity Branch, Bethesda, MD, ²Niams, Immunoregulation Section, Autoimmunity Branch, Bethesda, MD, ³National Human Genome Research Institute,National Institute of Health, Bethesda, MD, ⁴Medical research council mitochondria biology unit Cambridge ,UK, Cambridge, United Kingdom, ⁵Inflammatory Disease Section, National Human Genome Research Institute, Bethesda, MD, ⁶National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

Background/Purpose: TRAPS (Tumor necrosis factors receptor associated periodic fever syndrome) is an autosomal dominant autoinflammatory disease associated with missense mutations in TNFRSF1A (tumor necrosis factor…
Abstract Number: 1161 • 2013 ACR/ARHP Annual Meeting
Microrna-155 As a Proinflammatory Regulator via SHIP-1 Down-Regulation In Acute Gouty Arthritis
Hye Mi Jin¹, Young-Nan Cho¹, Seung-Jung Kee², Dong-Jin Park³, Yong-Wook Park³, Shin-Seok Lee⁴ and Tae-Jong Kim¹, ¹Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ³Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ⁴Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose: Gout is characterised by episodes of intense joint inflammation in response to intra-articular monosodium urate monohydrate (MSU) crystals. miR-155 is crucial for the proinflammatory…
Abstract Number: 1162 • 2013 ACR/ARHP Annual Meeting
The Role Of Microrna 155 In Innate Immunity and Arthritis
Antonia Puchner¹, Victoria Saferding², Eliana Goncalves-Alves³, Josef S. Smolen⁴, Kurt Redlich⁵ and Stephan Blueml⁶, ¹Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria, ⁵Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁶Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: MicroRNA 155 (miR155) has been demonstrated to be essential for the development of collagen induced arthritis by controlling the generation of autoreactive T and…
Abstract Number: 1163 • 2013 ACR/ARHP Annual Meeting
The Receptor For Advanced Glycation End Products (RAGE) As a Modulator Of Inflammatory Responses and Its Contribution To Gender-Specific Effects During Arthritis
Timo Wirth¹, Christoph Kessel¹, Philipp Becker², Toni Weinhage³, Nadine Nippe⁴ and Dirk Foell⁵, ¹Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, ²University of Muenster, Muenster, Germany, ³Pediatric Rheumatology and Immunology, University of Muenster, Münster, Germany, ⁴Department of Dermatology, University of Muenster, Münster, Germany, ⁵Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: The receptor for advanced glycation end products (RAGE) is a multi-ligand receptor expressed on various cells which interacts with a diverse class of ligands,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].